CMMB | Chemomab Therapeutics Ltd. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.8200 - 2.2668
52 Week Range	0.4200 - 2.5500
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	554,954
Average Volume	211,745
Shares Outstanding	14,359,190
Market Cap	27,210,665
Sector	Healthcare
Industry	Biotechnology
IPO Date	2019-02-12

Valuation
Profitability
Growth
Health
P/E Ratio	-1.79
Forward P/E Ratio	N/A
EPS	-1.06
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	20
Country	Israel
Website	CMMB

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

CMMB's peers: RNXT, ANEB, SABS, MNPR, ELDN, LEXX, NAVB, ZVSA, BDRX, ONCR, NLTX, SNTI, HILS, QNRX, LBPH, LUMO, IMUC, CLRB, BOLT, CINGW, CVKD

*Chart delayed

Analyzing fundamentals for CMMB we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see CMMB Fundamentals page.

Watching at CMMB technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on CMMB Technicals page.